VALIRX PLC

Regulatory Filings • Apr 12, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6465K

ValiRx PLC

12 April 2018

ValiRx Plc

("ValiRx" or the "Company")

Posting of Annual Report and Accounts

&

Notice of Annual General Meeting

London, UK, 12 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that its Annual Report and Accounts for the year ended 31 December 2017 has been published, is available on the Company's website, www.valirx.com and has been posted to registered shareholders.

The Company also advises that the Notice of its Annual General Meeting ("AGM") is now available on its website, www.valirx.com and has also been posted to registered shareholders.

The Company's AGM will be held on 8 May 2018 at 10.00 a.m. at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London, EC4A 1BN.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Satu Vainikka, Chief Executive	www.valirx.com Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Ludo Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited Colin Rowbury	Tel: +44 (0) 20 7399 9400

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASFSFAFFASEIL